A nonreplicating modified vaccinia Ankara (MVA) recombinant viral-vector vaccine expressing CMV antigens IE1, IE2, and pp65; administered as two intramuscular doses (5.0 x 10^8 pfu) to elicit CMV-specific cellular immunity (CD8+ CTLs and CD4+ Th1) for prevention of primary CMV after D+R− liver transplant.
Nonreplicating MVA viral-vector vaccine that expresses CMV antigens IE1, IE2, and pp65 in host cells, leading to antigen presentation via MHC I/II by dendritic cells and induction of CMV-specific cellular immunity (CD8+ cytotoxic T cells and CD4+ Th1 responses) to prevent primary CMV infection post–liver transplant.
YES
INDIRECT
The vaccine induces pp65-specific CD8+ T cells that recognize pp65-derived peptides on MHC I of CMV-infected cells and kill them via perforin/granzyme–mediated cytolysis.
An autologous, gene-modified CAR T-cell therapy engineered via lentiviral transduction with a KIR-based CAR targeting mesothelin (MSLN) on tumor cells to activate T-cell effector functions and cytotoxic killing.
Autologous T cells are lentivirally transduced to express a KIR-based CAR comprising an anti-mesothelin scFv fused to KIR2DS2 signaling with DAP12. Upon binding mesothelin on tumor cells, the KIR-CAR activates T-cell effector functions via ITAM signaling, promoting cytotoxic killing of mesothelin-expressing cancer cells, with the KIR architecture designed to enhance persistence and reduce exhaustion.
YES
DIRECT
KIR-based anti-mesothelin CAR T cells bind mesothelin and, via DAP12 ITAM signaling, kill target cells through T-cell cytotoxic mechanisms (perforin/granzyme and apoptosis pathways).
Investigational IV small-molecule inhibitor of the TRPV6 calcium channel intended to suppress Ca2+-dependent tumor growth and survival signaling.
Bispecific ligand–drug conjugate that targets folate receptor alpha (FRa) and the TRPV6 calcium channel on tumor cells; upon binding and internalization, it releases the camptothecin analog exatecan to inhibit topoisomerase I, blocking DNA replication and inducing cell-cycle arrest and apoptosis in FRa/TRPV6-expressing tumors.
YES
DIRECT
CBP-1019 binds FRa on tumor cells, is internalized, and releases the topoisomerase I inhibitor exatecan, which blocks DNA replication and triggers cell-cycle arrest and apoptosis in FRa-expressing cells.
Investigational IV small-molecule inhibitor of the TRPV6 calcium channel intended to suppress Ca2+-dependent tumor growth and survival signaling.
Bispecific ligand–drug conjugate that targets folate receptor alpha (FRa) and the TRPV6 calcium channel on tumor cells; upon binding and internalization, it releases the camptothecin analog exatecan to inhibit topoisomerase I, blocking DNA replication and inducing cell-cycle arrest and apoptosis in FRa/TRPV6-expressing tumors.
YES
DIRECT
CBP-1019 binds TRPV6 on tumor cells, is internalized, and releases the exatecan payload, a topoisomerase I inhibitor, causing DNA replication blockade and apoptosis of TRPV6-expressing cells.